APR-548
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for APR-548, covering 2025-03-07 to 2025-03-07. Get the full timeline:
Most recent: Clinical Trial Update: APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) [Phase 1]